Manufacture of pharmaceutical preparations
AGILERA PHARMA AS
Revenue 2024
NOK 357.6m
Operating profit
NOK −29.0m
Equity
NOK 15.0m
Incorporated
2021
Employees
137
Share capital
NOK 4.5m
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 357.6m | |
| Total operating costs | 386.6m | |
| Operating profit (EBIT) | −29.0m | |
| Net financial items | −3.5m | |
| Profit for the year | −34.8m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 149.2m | |
| of which current assets | 100.5m | |
| Equity | 15.0m | |
| Total liabilities | 134.2m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.